Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.

Trial Details

NCT ID

NCT06586255

Phase

PHASE1

Sponsor

Abramson Cancer Center at Penn Medicine

Status

RECRUITING

Cancer Type

Urothelial Carcinoma Bladder Cancer

Interventions

Concurrent Immunotherapy and Radiation Therapy

Locations (sample)

Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

Pure or mixed variant urothelial carcinoma
o Allowable mixed variant subtypes include:
squamous differentiation
glandular differentiation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →